ClinicalTrials.gg
CompletedNCT03939312Updated May 12, 2022Results posted

Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

A Phase 3 interventional study of Atogepant in Episodic Migraine, sponsored by Allergan. Completed at 113 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-05-12.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
685
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.

Enrollment
7th of 21
685 · median 468
Started
2019
with 1 other
Phase 3
15 of 21
3 open now
Registered
5th of 21
by date
Lead sponsor
7 of 21
Allergan

Among the 21 studies testing atogepant in Migraine Disorders, this one is the 7th largest by enrollment, is one of 2 that started in 2019, is one of 15 in phase 3, and was the 5th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About atogepant

atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing atogepant in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of atogepant 60 mg once a day for the prevention of migraine in participants with episodic migraine.

03

Conditions studied

  • Episodic Migraine

Keywords

  • Migraine
  • Aura
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written and participant privacy information (eg, written authorization for use and release of health and research study information) obtained from the participant prior to initiation of any study-specific procedures.
  • Participants must be using a medically acceptable and effective method of during the course of the entire study.
  • Eligible participants who completed the double-blind treatment period (Visit 7) and the follow-up period (Visit 8), if applicable, depending on the timing of study initiation, of Study 3101-301-002 (NCT03777059) without significant protocol deviations (eg, noncompliance to protocol-required procedures).

Exclusion criteria

Exclusion Criteria:

  • Female participant is pregnant, planning to become pregnant during the course of the study, or currently lactating. Women of must have a negative urine pregnancy test at Visit 1.
  • Hypertension as defined by sitting systolic BP > 160 mm Hg or sitting diastolic BP > 100 mm Hg at Visit 1.
  • Participants with hematologic, endocrine, cardiovascular, pulmonary, renal, hepatic, gastrointestinal, or neurologic disease.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
685 participants (actual)

Study arms

  • Experimental
    Atogepant 60 mg

    Participants received atogepant 60 mg, orally, once daily (QD) for up to 40 weeks.

    Drug: Atogepant

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least 1 Treatment-Emergent Adverse Event and Treatment-Emergent Serious Adverse Event (TEAEs/TESAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

    Time frame: From dose of study drug until 30 days following last dose of study drug (up to approximately Week 44)

Secondary outcomes

  1. Percentage of Participants With Potentially Clinically Significant (PCS) Laboratory Values as Assessed by the Investigator

    Clinical laboratory test values are considered PCS if they meet either the lower-limit or higher-limit PCS criteria defined in the categories below. Percentage of participants with PCS laboratory values are summarized for chemistry, hematology, and urinalysis. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during post-baseline are reported.

    Time frame: Up to Week 44

  2. Percentage of Participants With Potentially Clinically Significant (PCS) Electrocardiograms (ECGs) Findings as Assessed by the Investigator

    12-lead ECGs were performed at select study visits. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.

    Time frame: Up to Week 40

  3. Percentage of Participants With Potentially Clinically Significant (PCS) Vital Sign Measurements as Assessed by the Investigator

    PCS postbaseline vital sign values are summarized for categories: systolic and diastolic blood pressures \[sitting and standing\], pulse rate \[sitting and standing\], respiratory rate, temperature, weight. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.

    Time frame: Up to Week 44

  4. Number of Participants With Suicidal Ideation and Behaviour Using 5-Point Scale of Columbia-Suicide Severity Rating Scale (C-SSRS)

    C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. Suicidal ideation: Minimum total score 1, maximum total score 5; higher total scores indicate more suicidal ideation. Suicidal behavior: Minimum total score 0, maximum total score 4; higher total scores indicate more suicidal behavior.

    Time frame: OL Treatment Period: Up to Week 40; Safety Follow-up Period: Week 44

07

Results

Posted May 12, 2022

Participant flow

OL Treatment Period (40 Weeks)
Participant flow — OL Treatment Period (40 Weeks)
MilestoneAtogepant 60 mg
Started685
Completed511
Not completed174
Withdrew: Withdrawal criteria at visit 143
Withdrew: Adverse event25
Withdrew: Lack of efficacy4
Withdrew: Withdrawal by subject35
Withdrew: Lost to follow-up19
Withdrew: Pregnancy3
Withdrew: Protocol deviation16
Withdrew: Non-compliance with study drug4
Withdrew: Site terminated by sponsor3
Withdrew: Reason not specified22
Safety Follow-up 4 Weeks (Up to Week 44)
Participant flow — Safety Follow-up 4 Weeks (Up to Week 44)
MilestoneAtogepant 60 mg
Started640
Completed624
Not completed16
Withdrew: Withdrawal by subject12
Withdrew: Lost to follow-up4

Outcome measures

PrimaryPercentage of Participants With at Least 1 Treatment-Emergent Adverse Event and Treatment-Emergent Serious Adverse Event (TEAEs/TESAEs)

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

Time frame:
From dose of study drug until 30 days following last dose of study drug (up to approximately Week 44)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Treatment-Emergent Adverse Event and Treatment-Emergent Serious Adverse Event (TEAEs/TESAEs)
percentage of participantsAtogepant 60 mg
TEAEs62.5
TESAEs3.4
SecondaryPercentage of Participants With Potentially Clinically Significant (PCS) Laboratory Values as Assessed by the Investigator

Clinical laboratory test values are considered PCS if they meet either the lower-limit or higher-limit PCS criteria defined in the categories below. Percentage of participants with PCS laboratory values are summarized for chemistry, hematology, and urinalysis. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during post-baseline are reported.

Time frame:
Up to Week 44
Reported as:
Number · percentage of participants
Percentage of Participants With Potentially Clinically Significant (PCS) Laboratory Values as Assessed by the Investigator
percentage of participantsAtogepant 60 mg
Eosinophils Absolute Cell Count (10^9/L): > 2.0 × Upper Limit of Normal (ULN)0.3
Hematocrit (Ratio): < 0.9 × Lower Limit of Normal (LLN)1.5
Hematocrit (Ratio): > 1.1 × ULN0.3
Hemoglobin (g/L): < 0.9 × LLN2.2
Lymphocytes Absolute Cell Count (10^9/L): < 0.7 × LLN0.6
Lymphocytes Absolute Cell Count (10^9/L): > 1.3 × ULN0.3
Monocytes Absolute Cell Count (10^9/L): < 0.5 × LLN0.3
Neutrophils Absolute Cell Count (10^9/L): < 0.7 × LLN1.6
Neutrophils Absolute Cell Count (10^9/L): > 1.3 × ULN4.4
Platelet Count (Thrombocytes) (10^9/L): < 0.5 × LLN0.1
Platelet Count (Thrombocytes) (10^9/L): > 1.5 × ULN0.3
Red Blood Cell Count (10^12/L): < 0.9 × LLN2.4
Red Blood Cell Count (10^12/L): > 1.1 × ULN0.1
White Blood Cell Count (10^9/L): < 0.9 × LLN3.5
White Blood Cell Count (10^9/L): > 1.5 × ULN0.6
Alanine Aminotransferase (SGPT) (U/L): ≥ 3.0 × ULN0.3
Aspartate Aminotransferase (SGOT) (U/L): ≥ 3.0 × ULN0.4
Bicarbonate (HCO3) (mmol/L): < 0.9 × LLN0.7
Bilirubin, Total (umol/L): ≥ 1.5 × ULN0.3
Blood Urea Nitrogen (mmol/L): > 1.5 × ULN0.1
Creatine Kinase (U/L): > 2.0 × ULN5.0
Creatinine (umol/L): > 1.5 × ULN0.4
Glomerular Filtration Rate (GFR) Estimated Calculation (mL/min/1.73m^2): < 60 mL/min/1.73m^215.6
Glucose, Non-fasting (mmol/L): < 0.8 × LLN2.2
Glucose, Non-fasting (mmol/L): > 2.0 × ULN0.9
Phosphorus (mmol/L): < 0.9 × LLN1.6
Phosphorus (mmol/L): > 1.1 × ULN0.6
Potassium (mmol/L): > 1.1 × ULN2.2
Protein, Total (g/L): < 0.9 × LLN0.7
Uric Acid (Urate) (umol/L): > 1.2 × ULN0.7
Urine Glucose: At Least 1+0.9
Urine Protein: At Least 1+27.6
SecondaryPercentage of Participants With Potentially Clinically Significant (PCS) Electrocardiograms (ECGs) Findings as Assessed by the Investigator

12-lead ECGs were performed at select study visits. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.

Time frame:
Up to Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With Potentially Clinically Significant (PCS) Electrocardiograms (ECGs) Findings as Assessed by the Investigator
percentage of participantsAtogepant 60 mg
QRS Duration, Single Beat (msec): ≥ 150 milliseconds (msecs)0.3
PR interval, Single Beat (msec): ≥ 250 msecs0.5
QTcB interval, Single Beat (msec): > 500 msecs0.2
QTcB interval, Single Beat (msec): Increase > 60 msecs0.3
QTcF interval, Single Beat (msec): Increase > 60 msecs0.2
QTcF interval, Single Beat (msec): >450 msecs3.4
QTcF interval, Single Beat (msec): >480 msecs0.1
SecondaryPercentage of Participants With Potentially Clinically Significant (PCS) Vital Sign Measurements as Assessed by the Investigator

PCS postbaseline vital sign values are summarized for categories: systolic and diastolic blood pressures \[sitting and standing\], pulse rate \[sitting and standing\], respiratory rate, temperature, weight. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.

Time frame:
Up to Week 44
Reported as:
Number · percentage of participants
Percentage of Participants With Potentially Clinically Significant (PCS) Vital Sign Measurements as Assessed by the Investigator
percentage of participantsAtogepant 60 mg
Systolic Blood Pressure Sitting (mmHg): ≤ 90 and Decrease of ≥ 201.9
Systolic Blood Pressure Standing (mmHg): ≤ 90 and Decrease of ≥ 200.7
Systolic Blood Pressure Standing (mmHg): ≥ 180 and Increase of ≥ 200.1
Standing - Sitting Systolic Blood Pressure (mmHg): ≤ -209.8
Diastolic Blood Pressure Sitting (mmHg): ≤ 50 and Decrease of ≥ 150.6
Diastolic Blood Pressure Sitting (mmHg): ≥ 105 and Increase of ≥ 151.0
Diastolic Blood Pressure Standing (mmHg): ≤ 50 and Decrease of ≥ 150.7
Diastolic Blood Pressure Standing (mmHg): ≥ 105 and Increase of ≥ 151.5
Standing - Sitting Diastolic Blood Pressure (mmHg): ≤ -157.4
Pulse Rate Sitting (beats/min): ≤ 50 and Decrease of ≥ 150.3
Pulse Rate Standing (beats/min): ≤ 50 and Decrease of ≥ 150.4
Pulse Rate Standing (beats/min): ≥ 120 and Increase of ≥ 151.8
Standing - Sitting Pulse Rate (beats/min): ≥ 256.8
Weight (kg): Decrease of ≥ 7 percent (%)23.9
Weight (kg): Increase of ≥ 7%9.2
SecondaryNumber of Participants With Suicidal Ideation and Behaviour Using 5-Point Scale of Columbia-Suicide Severity Rating Scale (C-SSRS)

C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. Suicidal ideation: Minimum total score 1, maximum total score 5; higher total scores indicate more suicidal ideation. Suicidal behavior: Minimum total score 0, maximum total score 4; higher total scores indicate more suicidal behavior.

Time frame:
OL Treatment Period: Up to Week 40; Safety Follow-up Period: Week 44
Reported as:
Count of participants · Participants
Number of Participants With Suicidal Ideation and Behaviour Using 5-Point Scale of Columbia-Suicide Severity Rating Scale (C-SSRS)
ParticipantsAtogepant 60 mgSafety Follow-up Period
Suicidal Ideation41
Suicidal Behavior00

Adverse events

Collected over From dose of study drug until 30 days following last dose of study drug (up to approximately Week 44). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atogepant 60 mg0/685 (0%)23/685 (3.4%)71/685 (10.4%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventAtogepant 60 mg
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/685
Road traffic accidentInjury, poisoning and procedural complications2/685
Abortion spontaneousPregnancy, puerperium and perinatal conditions2/685
GastritisGastrointestinal disorders1/685
Non-cardiac chest painGeneral disorders1/685
Systemic inflammatory response syndromeGeneral disorders1/685
CholelithiasisHepatobiliary disorders1/685
Clostridium difficile colitisInfections and infestations1/685
Corona virus infectionInfections and infestations1/685
Staphylococcal infectionInfections and infestations1/685
Most frequent other events
Most frequent other events
EventAtogepant 60 mg
Upper respiratory tract infectionInfections and infestations38/685
Urinary tract infectionInfections and infestations36/685

Baseline characteristics

Safety population included all participants who received at least 1 dose of atogepant in this extension study.

Age, Continuous
Age, Continuous(years)Atogepant 60 mg
Mean41.8 ± 12.30
Sex: Female, Male
Sex: Female, Male(Participants)Atogepant 60 mg
Female604
Male81
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Atogepant 60 mg
Hispanic or Latino54
Not Hispanic or Latino631
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Atogepant 60 mg
American Indian or Alaska Native3
Asian9
Native Hawaiian or Other Pacific Islander0
Black or African American86
White578
More than one race8
Unknown or Not Reported1
08

Study locations

113 sites
  • Synexus Clinical Research US, Inc.
    Chandler, Arizona 85224, United States
  • Alea Research
    Phoenix, Arizona 85012, United States
  • Central Phoenix Medical Clinic
    Phoenix, Arizona 85020, United States
  • Orange Grove Family Practice
    Tucson, Arizona 85741, United States
  • Principals Research Group
    Hot Springs, Arkansas 71901, United States
  • Arkansas Clinical Research
    Little Rock, Arkansas 72205, United States
  • Baptist Health Center for Clinical Research
    Little Rock, Arkansas 72205, United States
  • Med Center Medical Clinic
    Carmichael, California 95608, United States
  • Neuro Pain Medical Center
    Fresno, California 93710, United States
  • California Headache and Balance Center
    Fresno, California 93720, United States
  • Grossmont Center for Clinical Research
    La Mesa, California 91942, United States
  • Paradigm Clinical Research Centers, Inc
    La Mesa, California 91942, United States
  • Torrance Clinical Research Institute, Inc.
    Lomita, California 90731, United States
  • Long Beach Clinical Trials Services
    Long Beach, California 90806, United States
  • Pharmacology Research Institute
    Newport Beach, California 92660, United States
  • Newport Beach Clinical Research Associates
    Newport Beach, California 92663, United States
  • Excell Research, Inc.
    Oceanside, California 92056, United States
  • Rancho Cucamonga Clinical Trials
    Rancho Cucamonga, California 91730, United States
  • Desert Valley Research
    Redlands, California 92374, United States
  • George J. Rederich, M.D. Inc.
    Redondo Beach, California 90277, United States
  • Optimus Medical Group
    San Francisco, California 94102, United States
  • California Neuroscience Research
    Sherman Oaks, California 91403, United States
  • Alpine Clinical Research Center
    Boulder, Colorado 80301, United States
  • Colorado Springs Neurological Associates
    Colorado Springs, Colorado 80907, United States
  • Colorado Neurological Institute
    Englewood, Colorado 80113, United States
  • New England Institute for Clinical Research
    Stamford, Connecticut 06905, United States
  • Aventura Neurological Associates
    Aventura, Florida 33180, United States
  • Neurology Offices of South Florida
    Boca Raton, Florida 33428, United States
  • Sarkis Clinical Trials- Gainesville
    Gainesville, Florida 32607, United States
  • Westside Center for Clinical Research
    Jacksonville, Florida 32205, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Well Pharma Medical Research, Corp
    Miami, Florida 33173, United States
  • Clinical Neuroscience Solutions
    Orlando, Florida 32801, United States
  • Neurology Associates of Ormond Beach
    Ormond Beach, Florida 32174, United States
  • Meridien Research
    Saint Petersburg, Florida 33709, United States
  • Sarasota Memorial Hospital Clinical Research Center
    Sarasota, Florida 34239, United States
  • Axiom Clinical Research of Florida
    Tampa, Florida 33609, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Neurotrials Research
    Atlanta, Georgia 30328, United States
  • Pediatric and Adolescent NeuroDevelopmental Associates (PANDA) Neurology
    Atlanta, Georgia 30328, United States
  • Synexus Clinical Research, Inc
    Atlanta, Georgia 30328, United States
  • Meridian Clinical Research, LLC
    Savannah, Georgia 31406, United States
  • Diamond Headache Clinic Ltd
    Chicago, Illinois 60642, United States
  • JWM Neurology
    Indianapolis, Indiana 46256, United States
  • Deaconess Clinic - Gateway Health Center
    Newburgh, Indiana 47630, United States
  • PMG Research, Inc. d/b/a PMG Research of McFarland Clinic
    Ames, Iowa 50010, United States
  • Heartland Research Associates, LLC
    Newton, Kansas 67114, United States
  • College Park Family Care Center
    Overland Park, Kansas 66212, United States
  • Collective Medical Research
    Prairie Village, Kansas 66208, United States
  • Heartland Research Associates, LLC - An AMR Company
    Wichita, Kansas 67205, United States
  • Heartland Research Associates, LLC - An AMR Company
    Wichita, Kansas 67207, United States
  • DelRicht Research
    New Orleans, Louisiana 70124, United States
  • Pharmasite Research, Inc.
    Baltimore, Maryland 21208, United States
  • John R. Graham Headache Center Brigham and Women's Faulkner Hospital
    Boston, Massachusetts 02103, United States
  • BTC of New Bedford
    New Bedford, Massachusetts 02740, United States
  • Clinical Research Institute
    Minneapolis, Minnesota 55402, United States
  • The Headache Center
    Ridgeland, Mississippi 39157, United States
  • StudyMetrix Research
    Saint Peters, Missouri 63303, United States
  • Clinvest Research LLC
    Springfield, Missouri 65810, United States
  • Synexus Clinical Research US, Inc.
    Omaha, Nebraska 68144, United States
  • Bio Behavioral Health
    Toms River, New Jersey 08755, United States
  • Albuquerque Clinical Trials
    Albuquerque, New Mexico 87102, United States
  • Dent Neurosciences Research Center
    Amherst, New York 14226, United States
  • PMG Research of Charlotte, LLC
    Charlotte, North Carolina 28209, United States
  • Raleigh Neurology Associates, P.A.
    Raleigh, North Carolina 27607, United States
  • PMG Research of Raleigh, LLC
    Raleigh, North Carolina 27609, United States
  • PMG Research of Rocky Mount, LLC
    Rocky Mount, North Carolina 27804, United States
  • Wilmington Health, PLLC
    Wilmington, North Carolina 28401, United States
  • Piedmont Medical Research of Winston-Salem
    Winston-Salem, North Carolina 27103, United States
  • Synexus Clinical Research US, Inc.
    Akron, Ohio 44311, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Patient Priority Clinical Sites
    Cincinnati, Ohio 45215, United States
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
  • New Horizons Clinical Research
    Cincinnati, Ohio 45242, United States
  • Aventiv Research Inc
    Columbus, Ohio 43212, United States
  • Ohio Clinical Research, LLC
    Lyndhurst, Ohio 44124, United States
  • OK Clinical Research, LLC
    Edmond, Oklahoma 73034, United States
  • Lynn Institute of Norman
    Norman, Oklahoma 72069, United States
  • Tulsa Clinical Research
    Tulsa, Oklahoma 74136, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Preferred Primary Care Physicians
    Pittsburgh, Pennsylvania 15236, United States
  • Frontier Clinical Research, LLC
    Smithfield, Pennsylvania 15478, United States
  • Preferred Primary Care Physicians, Jacob Murphy
    Uniontown, Pennsylvania 15401, United States
  • Abington Neurological Associates
    Willow Grove, Pennsylvania 19090, United States
  • Partners in Clinical Research, LLC
    Cumberland, Rhode Island 02864, United States
  • Ocean State Clinical Research Partners
    Lincoln, Rhode Island 02865, United States
  • Primary Care Associates/Synexus Clinical
    Anderson, South Carolina 29621, United States
  • Clinical Trials of South Carolina
    Charleston, South Carolina 29406, United States
  • Hillcrest Family Practice
    Simpsonville, South Carolina 29681, United States
  • ClinSearch
    Chattanooga, Tennessee 37421, United States
  • Holston Medical Group
    Kingsport, Tennessee 37760, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • Psychiatry & Psychotherapy Partners Austin
    Austin, Texas 78737, United States
  • Tekton Research
    Austin, Texas 78745, United States
  • Synexus-US
    Dallas, Texas 75234, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Ventavia Research Group
    Fort Worth, Texas 76104, United States
  • Centex Studies, Inc.
    Houston, Texas 77058, United States
  • Protenium Clinical Research
    Hurst, Texas 76054, United States
  • Clinical Trials of Texas
    San Antonio, Texas 78229, United States

Showing the first 100 of 113 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Boinpally R, McNamee B, Yao L, Butler M, McGeeney D, Borbridge L, Periclou A. A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover Trial. Clin Pharmacol Drug Dev. 2021 Sep;10(9):1099-1107. doi: 10.1002/cpdd.940. Epub 2021 May 4. PubMed 33942560 ↗
  • Min KC, Kraft WK, Bondiskey P, Colon-Gonzalez F, Liu W, Xu J, Panebianco D, Mixson L, Dockendorf MF, Matthews CZ, Boinpally R. Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults. Clin Transl Sci. 2021 Mar;14(2):599-605. doi: 10.1111/cts.12917. Epub 2020 Nov 24. PubMed 33142014 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing, please refer to the link below.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Mar 2021, 22 months.

Results were first posted in May 2022, 1 year 1 month after primary completion.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 22 months is above that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2019
First posted
May 6, 2019
StartActual
May 6, 2019
Primary completionActual
Mar 31, 2021
CompletionActual
Mar 31, 2021
Results first posted
May 12, 2022
Last update
May 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03939312
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
May 6, 2019
Start date
May 6, 2019
Primary completion
Mar 31, 2021
Completion
Mar 31, 2021
Results posted
May 12, 2022
Last update
May 12, 2022

Study contacts

Joel Trugman, MD
study director · Allergan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atogepant

Start the discussion